

# Luciano Mutti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3151103/publications.pdf>

Version: 2024-02-01

154  
papers

5,926  
citations

76196

40  
h-index

85405

71  
g-index

162  
all docs

162  
docs citations

162  
times ranked

6335  
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. <i>European Respiratory Journal</i> , 2010, 35, 479-495.	3.1	548
2	Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. <i>Journal of Pathology</i> , 2001, 193, 468-475.	2.1	326
3	Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1104-1111.	5.1	326
4	Repurposing atovaquone: Targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells. <i>Oncotarget</i> , 2016, 7, 34084-34099.	0.8	171
5	MicroRNA Signature of Malignant Mesothelioma with Potential Diagnostic and Prognostic Implications. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2010, 42, 312-319.	1.4	155
6	ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. <i>European Respiratory Journal</i> , 2020, 55, 1900953.	3.1	151
7	BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. <i>Oncogene</i> , 2008, 27, 1189-1197.	2.6	144
8	Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 5076-5081.	3.2	138
9	SV40 replication in human mesothelial cells induces HGF/Met receptor activation: A model for viral-related carcinogenesis of human malignant mesothelioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 12032-12037.	3.3	135
10	Advances in the systemic therapy of malignant pleural mesothelioma. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 136-147.	4.3	124
11	Association of SV40 with human tumours. <i>Seminars in Cancer Biology</i> , 2001, 11, 49-61.	4.3	99
12	SV40 Enhances the Risk of Malignant Mesothelioma among People Exposed to Asbestos: A Molecular Epidemiologic Case-Control Study. <i>Cancer Research</i> , 2005, 65, 3049-3052.	0.4	90
13	Bortezomib Inhibits Nuclear Factor- $\kappa$ B-Dependent Survival and Has Potent In vivo Activity in Mesothelioma. <i>Clinical Cancer Research</i> , 2007, 13, 5942-5951.	3.2	90
14	Estrogen Receptor- $\beta$ Affects the Prognosis of Human Malignant Mesothelioma. <i>Cancer Research</i> , 2009, 69, 4598-4604.	0.4	87
15	Scientific Advances and New Frontiers in Mesothelioma Therapeutics. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1269-1283.	0.5	87
16	Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. <i>British Journal of Cancer</i> , 2002, 86, 979-982.	2.9	83
17	SV40-Dependent AKT Activity Drives Mesothelial Cell Transformation after Asbestos Exposure. <i>Cancer Research</i> , 2005, 65, 5256-5262.	0.4	81
18	Targeting hypoxic response for cancer therapy. <i>Oncotarget</i> , 2016, 7, 13464-13478.	0.8	80

#	ARTICLE	IF	CITATIONS
19	Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion. <i>Lung Cancer</i> , 2001, 31, 303-310.	0.9	76
20	HLA-B*44 and C*01 Prevalence Correlates with Covid19 Spreading across Italy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5205.	1.8	73
21	The Presence of Simian-Virus 40 Sequences in Mesothelioma and Mesothelial Cells Is Associated with High Levels of Vascular Endothelial Growth Factor. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2002, 26, 189-193.	1.4	67
22	Imatinib Mesylate Enhances Therapeutic Effects of Gemcitabine in Human Malignant Mesothelioma Xenografts. <i>Clinical Cancer Research</i> , 2008, 14, 541-548.	3.2	65
23	Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases. <i>Mutation Research - Reviews in Mutation Research</i> , 2008, 659, 126-136.	2.4	64
24	The role of microenvironment and immunity in drug response in leukemia. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 414-426.	1.9	62
25	Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis. <i>European Respiratory Journal</i> , 1999, 13, 527-534.	3.1	59
26	Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 59, 149-150.	1.1	59
27	Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma. <i>Genes Chromosomes and Cancer</i> , 2000, 29, 173-179.	1.5	56
28	Estrogen Receptor $\beta$ Exerts Tumor Repressive Functions in Human Malignant Pleural Mesothelioma via EGFR Inactivation and Affects Response to Gefitinib. <i>PLoS ONE</i> , 2010, 5, e14110.	1.1	56
29	Negative modulation of mitochondrial oxidative phosphorylation by epigallocatechin-3 gallate leads to growth arrest and apoptosis in human malignant pleural mesothelioma cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 2085-2096.	1.8	56
30	Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism. <i>Scientific Reports</i> , 2017, 7, 3140.	1.6	55
31	Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesothelioma. <i>International Journal of Cancer</i> , 2007, 120, 2739-2743.	2.3	53
32	Raltitrexed + Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. <i>Lung Cancer</i> , 2005, 48, 429-434.	0.9	51
33	ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. <i>European Journal of Cardio-thoracic Surgery</i> , 2020, 58, 1-24.	0.6	50
34	Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 835-842.	1.9	49
35	Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. <i>Thorax</i> , 2007, 62, 690-695.	2.7	46
36	Erionite and asbestos differently cause transformation of human mesothelial cells. <i>International Journal of Cancer</i> , 2007, 121, 12-20.	2.3	46

#	ARTICLE	IF	CITATIONS
37	Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations. <i>Journal of Thoracic Oncology</i> , 2022, 17, 873-889.	0.5	44
38	Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives. <i>Translational Lung Cancer Research</i> , 2020, 9, S100-S119.	1.3	43
39	BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment. <i>International Journal of Molecular Sciences</i> , 2019, 20, 429.	1.8	42
40	Genetic susceptibility to malignant mesothelioma and exposure to asbestos: The influence of the familial factor. <i>Mutation Research - Reviews in Mutation Research</i> , 2008, 658, 162-171.	2.4	41
41	Comparison between Plasma and Serum Osteopontin Levels: Usefulness in Diagnosis of Epithelial Malignant Pleural Mesothelioma. <i>International Journal of Biological Markers</i> , 2010, 25, 164-170.	0.7	41
42	Epigallocatechin gallate induces mesothelioma cell death via H <sub>2</sub> O <sub>2</sub> -dependent Ca <sup>2+</sup> channel opening. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 2667-2678.	1.6	40
43	New Agents in the Management of Advanced Mesothelioma. <i>Seminars in Oncology</i> , 2005, 32, 336-350.	0.8	37
44	Surgery for malignant pleural mesothelioma: an international guidelines review. <i>Journal of Thoracic Disease</i> , 2018, 10, S285-S292.	0.6	37
45	HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis. <i>Cells</i> , 2020, 9, 1964.	1.8	37
46	Expression and activity of eIF6 trigger Malignant Pleural Mesothelioma growth in vivo. <i>Oncotarget</i> , 2015, 6, 37471-37485.	0.8	37
47	Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma. <i>Biologics: Targets and Therapy</i> , 2008, 2, 601.	3.0	36
48	Perifosine as a Potential Novel Anti-Cancer Agent Inhibits EGFR/MET-AKT Axis in Malignant Pleural Mesothelioma. <i>PLoS ONE</i> , 2012, 7, e36856.	1.1	36
49	Estrogen receptor $\beta$ activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo. <i>Oncogenesis</i> , 2013, 2, e72-e72.	2.1	34
50	Primary human mesothelioma cells express class II MHC, ICAM-1 and B7-2 and can present recall antigens to autologous blood lymphocytes. , 1998, 78, 740-749.		33
51	Malignant pleural mesothelioma: current treatments and emerging drugs. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 423-437.	1.0	33
52	PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1. <i>Journal of Cellular and Molecular Medicine</i> , 2013, 17, 233-241.	1.6	33
53	The Biochemical Role of the Human NEIL1 and NEIL3 DNA Glycosylases on Model DNA Replication Forks. <i>Genes</i> , 2019, 10, 315.	1.0	33
54	Simian virus 40 is not a cofactor in the pathogenesis of environmentally induced malignant pleural mesothelioma in Turkey. <i>Anticancer Research</i> , 2000, 20, 891-4.	0.5	32

#	ARTICLE	IF	CITATIONS
55	Simian virus 40 sequences in blood specimens from healthy individuals of Casale Monferrato, an industrial town with a history of asbestos pollution. <i>Journal of Infection</i> , 2009, 58, 53-60.	1.7	31
56	Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma. <i>European Journal of Cancer</i> , 2012, 48, 2983-2992.	1.3	30
57	Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival. <i>Journal of Pathology</i> , 2002, 197, 218-223.	2.1	29
58	Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma. <i>JAMA Network Open</i> , 2022, 5, e221490.	2.8	29
59	A Polysome-Based microRNA Screen Identifies miR-24-3p as a Novel Promigratory miRNA in Mesothelioma. <i>Cancer Research</i> , 2018, 78, 5741-5753.	0.4	28
60	A Molecular Epidemiology Case Control Study on Pleural Malignant Mesothelioma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1741-1746.	1.1	27
61	P53-regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma. <i>Cell Death and Disease</i> , 2020, 11, 748.	2.7	27
62	MSLN Gene Silencing Has an Anti-Malignant Effect on Cell Lines Overexpressing Mesothelin Deriving from Malignant Pleural Mesothelioma. <i>PLoS ONE</i> , 2014, 9, e85935.	1.1	26
63	High frequency of micronuclei in peripheral blood lymphocytes as index of susceptibility to pleural malignant mesothelioma. <i>Cancer Research</i> , 2002, 62, 5418-9.	0.4	26
64	Preclinical Demonstration of Synergistic Active Nutrients/Drug (AND) Combination as a Potential Treatment for Malignant Pleural Mesothelioma. <i>PLoS ONE</i> , 2013, 8, e58051.	1.1	25
65	A Common Polymorphism Within MSLN Affects miR-611 Binding Site and Soluble Mesothelin Levels in Healthy People. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1662-1668.	0.5	25
66	Expression status of candidate genes in mesothelioma tissues and cell lines. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2015, 771, 6-12.	0.4	25
67	In vitro and in vivo characterization of highly purified Human Mesothelioma derived cells. <i>BMC Cancer</i> , 2010, 10, 54.	1.1	24
68	SV40 and human brain tumors. <i>International Journal of Cancer</i> , 2003, 106, 140-142.	2.3	23
69	Tremelimumab for the treatment of malignant mesothelioma. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1819-1829.	1.4	23
70	Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma. <i>International Journal of Biological Markers</i> , 2010, 25, 164-70.	0.7	23
71	Taurolidine and oxidative stress: a rationale for local treatment of mesothelioma. <i>European Respiratory Journal</i> , 2009, 34, 1399-1407.	3.1	21
72	Gefitinib Targets EGFR Dimerization and ERK1/2 Phosphorylation to Inhibit Pleural Mesothelioma Cell Proliferation. <i>Current Cancer Drug Targets</i> , 2010, 10, 176-191.	0.8	21

#	ARTICLE	IF	CITATIONS
73	The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells. <i>Stem Cell Research and Therapy</i> , 2017, 8, 119.	2.4	21
74	Switching off malignant mesothelioma: exploiting the hypoxic microenvironment. <i>Genes and Cancer</i> , 2017, 7, 340-354.	0.6	20
75	Anti-CTLA-4 therapy for malignant mesothelioma. <i>Immunotherapy</i> , 2017, 9, 273-280.	1.0	19
76	PRMT5 silencing selectively affects <i>MTAP</i> -deleted mesothelioma: In vitro evidence of a novel promising approach. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 5565-5577.	1.6	19
77	Immunotherapy beyond progression in patients with advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 2391-2400.	1.3	19
78	Interleukin-2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitro. <i>Journal of Cellular Physiology</i> , 2000, 185, 126-134.	2.0	18
79	Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines. <i>Genes and Cancer</i> , 2017, 8, 438-452.	0.6	18
80	Risk of malignant pleural mesothelioma and polymorphisms in genes involved in the genome stability and xenobiotics metabolism. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2009, 671, 76-83.	0.4	17
81	Expression and regulation of B7 $\chi$ 3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: Immunotherapeutic implications. <i>Journal of Cellular Physiology</i> , 2011, 226, 2595-2600.	2.0	17
82	CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8391.	1.8	17
83	In Arrayed Ranks: Array Technology in the Study of Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2009, 4, 411-425.	0.5	16
84	Coronavirus Disease (Covid-19): What Are We Learning in a Country With High Mortality Rate?. <i>Frontiers in Immunology</i> , 2020, 11, 1208.	2.2	16
85	Therapies currently in Phase II trials for malignant pleural mesothelioma. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1255-1263.	1.9	15
86	Sirtuin Family Members Selectively Regulate Autophagy in Osteosarcoma and Mesothelioma Cells in Response to Cellular Stress. <i>Frontiers in Oncology</i> , 2019, 9, 949.	1.3	14
87	Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade. <i>Frontiers in Oncology</i> , 2021, 11, 684110.	1.3	14
88	The detection of simian virus 40 in human tumors by polymerase chain reaction. <i>Monaldi Archives for Chest Disease</i> , 1998, 53, 202-10.	0.3	14
89	BAK and NOXA Are Critical Determinants of Mitochondrial Apoptosis Induced by Bortezomib in Mesothelioma. <i>PLoS ONE</i> , 2013, 8, e65489.	1.1	13
90	Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals. <i>Occupational and Environmental Medicine</i> , 2017, 74, 457-464.	1.3	13

#	ARTICLE	IF	CITATIONS
91	Chemoprevention of asbestos-linked cancers: a systematic review. <i>Anticancer Research</i> , 2012, 32, 1005-13.	0.5	13
92	Immunotherapy advances for mesothelioma treatment. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 799-814.	1.1	12
93	Identification of Overexpressed Genes in Malignant Pleural Mesothelioma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2738.	1.8	12
94	Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 933-944.	1.9	11
95	p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification. <i>Journal of Translational Medicine</i> , 2018, 16, 282.	1.8	11
96	Tissue expression of lactate transporters (MCT1 and MCT4) and prognosis of malignant pleural mesothelioma (brief report). <i>Journal of Translational Medicine</i> , 2020, 18, 341.	1.8	11
97	When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?. <i>Frontiers in Endocrinology</i> , 2019, 10, 89.	1.5	10
98	Protein disulfide isomerase A1 regulates breast cancer cell immunorecognition in a manner dependent on redox state. <i>Oncology Reports</i> , 2020, 44, 2406-2418.	1.2	9
99	Prognostic significance of presence and reduplication of basal lamina in malignant pleural mesothelioma. <i>Human Pathology</i> , 2000, 31, 1341-1345.	1.1	8
100	Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: A possible mechanism of interleukin-2-mediated cytotoxicity?. <i>Lung Cancer</i> , 2002, 38, 159-162.	0.9	8
101	Sustained Expression of Steroid Receptor Coactivator SRC-2/TIF-2 is Associated with Better Prognosis in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2012, 7, 243-248.	0.5	8
102	Current and prospective pharmacotherapies for the treatment of pleural mesothelioma. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 455-465.	0.5	8
103	ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe. <i>European Respiratory Journal</i> , 2018, 52, 1800610.	3.1	8
104	Blood cell redistribution in the lung after administration of recombinant human granulocyte-macrophage colony-stimulating factor. <i>European Respiratory Journal</i> , 1995, 8, 1566-71.	3.1	8
105	A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma. <i>Cancers</i> , 2022, 14, 2527.	1.7	8
106	Synergistic effect of the anti-HER-2/neu antibody and cisplatin in immortalized and primary mesothelioma cell lines. <i>Journal of Cellular Physiology</i> , 2002, 193, 37-41.	2.0	7
107	Translational therapies for malignant pleural mesothelioma. <i>Expert Review of Respiratory Medicine</i> , 2010, 4, 249-260.	1.0	7
108	Insight into glucocorticoid receptor signalling through interactome model analysis. <i>PLoS Computational Biology</i> , 2017, 13, e1005825.	1.5	7



#	ARTICLE	IF	CITATIONS
109	Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis. <i>Life</i> , 2021, 11, 1235.	1.1	7
110	CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma?. <i>Lancet Oncology</i> , The, 2022, 23, e13.	5.1	7
111	Simian virus 40-like DNA sequences and large-T antigen-retinoblastoma family protein pRb2/p130 interaction in human mesothelioma. <i>Developments in Biological Standardization</i> , 1998, 94, 47-53.	0.2	7
112	Simian virus 40 and malignant mesothelioma (Review). <i>International Journal of Oncology</i> , 2003, 22, 187.	1.4	6
113	Endoplasmic reticulum stress, unfolded protein response and autophagy contribute to resistance to glucocorticoid treatment in human acute lymphoblastic leukaemia cells. <i>International Journal of Oncology</i> , 2020, 57, 835-844.	1.4	6
114	Expression of intercellular adhesion molecule-1 (ICAM-1) by reactive mesothelial cells in pleural effusions. <i>Pathologica</i> , 1993, 85, 725-8.	1.3	6
115	Transforming growth factor-beta released by PPD-presenting malignant mesothelioma cells inhibits interferon-gamma synthesis by an anti-PPD CD4+ T-cell clone. <i>International Journal of Molecular Medicine</i> , 2003, 11, 161-7.	1.8	6
116	Will Antiangiogenic Agents be a Future for Mesothelioma Therapy?. <i>Current Medicinal Chemistry</i> , 2010, 17, 3069-3079.	1.2	5
117	What can independent research for mesothelioma achieve to treat this orphan disease?. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 719-732.	1.9	5
118	Evidence for and implications of SV40-like sequences in human mesotheliomas and osteosarcomas. <i>Developments in Biological Standardization</i> , 1998, 94, 33-40.	0.2	5
119	The therapeutic potential of the novel ribonuclease ranpirnase (Onconase®) in the treatment of malignant mesothelioma. <i>Oncology Reviews</i> , 2008, 2, 61-65.	0.8	4
120	Is There Already a Need of Reckoning on Cancer Immunotherapy?. <i>Frontiers in Pharmacology</i> , 2021, 12, 638279.	1.6	4
121	Liquid Biopsies from Pleural Effusions and Plasma from Patients with Malignant Pleural Mesothelioma: A Feasibility Study. <i>Cancers</i> , 2021, 13, 2445.	1.7	4
122	Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia. <i>PLoS ONE</i> , 2017, 12, e0178606.	1.1	4
123	Evaluation of the Role of p53 Tumour Suppressor Posttranslational Modifications and TTC5 Cofactor in Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13198.	1.8	4
124	Transforming growth factor- $\beta^2$ released by PPD-presenting malignant mesothelioma cells inhibits interferon- $\gamma^3$ synthesis by an anti-PPD CD4+ T-cell clone. <i>International Journal of Molecular Medicine</i> , 2003, 11, 161.	1.8	3
125	Circulating tumor cells as a diagnostic test for malignant pleural mesothelioma. <i>Expert Opinion on Medical Diagnostics</i> , 2012, 6, 171-173.	1.6	3
126	79 The RON (MST1R)/MSP pathway is a potential therapeutic target in malignant pleural mesothelioma. <i>Lung Cancer</i> , 2014, 83, S29-S30.	0.9	3



#	ARTICLE	IF	CITATIONS
127	P1.05-021 circRNAs: Potential Novel Biomarkers for the Early Detection of Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S626-S627.	0.5	3
128	Tumour Treating Fields for mesothelioma. Lancet Oncology, The, 2020, 21, e8.	5.1	3
129	The Expanded p53 Interactome as a Predictive Model for Cancer Therapy. Genomics and Computational Biology, 2015, 1, 20.	0.7	3
130	RAMES study: is there really a role for VEGF inhibition in mesothelioma?. Lancet Oncology, The, 2021, 22, e532.	5.1	3
131	Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma. Genes Chromosomes and Cancer, 2001, 30, 111-111.	1.5	2
132	Malignant pleural mesothelioma: new ideas needed. Lung Cancer Management, 2015, 4, 201-203.	1.5	2
133	A Glimpse in the Future of Malignant Mesothelioma Treatment. Frontiers in Pharmacology, 2021, 12, 809337.	1.6	2
134	Abemaciclib for malignant pleural mesothelioma. Lancet Oncology, The, 2022, 23, e237.	5.1	2
135	52 Expression of the receptor MST1R/RON and its ligand MSP in malignant pleural mesothelioma. Lung Cancer, 2011, 71, S18.	0.9	1
136	Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal End Point?. Journal of Thoracic Oncology, 2022, 17, e10-e12.	0.5	1
137	64 Macrophage stimulating protein (MSP) up-regulates the Src kinases in malignant pleural mesothelioma. Lung Cancer, 2012, 75, S21.	0.9	0
138	High Expression of Macrophage Stimulating Protein (MSP) Correlates with Survival Benefit in Malignant Pleural Mesothelioma. Annals of Oncology, 2012, 23, ix495.	0.6	0
139	87 Expression of SDHB in malignant pleural mesothelioma. Lung Cancer, 2013, 79, S30.	0.9	0
140	82 Inhibition of RON (MST1R) induces apoptosis and decreases the cellular migration and proliferation capacity of mesothelioma cells. Lung Cancer, 2013, 79, S29.	0.9	0
141	New standard for assessing asbestos exposure and its consequences?. Occupational and Environmental Medicine, 2016, 73, 709.1-710.	1.3	0
142	86 When RON MET TAM: potential interventions for mesothelioma therapy. Lung Cancer, 2016, 91, S31.	0.9	0
143	56: Multiple RTK targeting as a therapeutic option in malignant pleural mesothelioma. Lung Cancer, 2017, 103, S26.	0.9	0
144	P3.03-008 Hypoxia-Induced Changes in microRNA Levels Contribute to Drug Resistance in a 3D Model of Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2017, 12, S1348.	0.5	0

#	ARTICLE	IF	CITATIONS
145	P3.03-021 When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?. Journal of Thoracic Oncology, 2017, 12, S1356-S1357.	0.5	0
146	8: Are circRNAs potentially useful for the early detection of lung cancer?. Lung Cancer, 2017, 103, S4-S5.	0.9	0
147	DKK1 stabilization as a new malignant pleural mesothelioma therapeutic avenue. Annals of Oncology, 2017, 28, ii56.	0.6	0
148	P1.09-007 Targeting MET/TAM Receptors in Mesothelioma: Are Multi-TKIs Superior to Specific TKI?. Journal of Thoracic Oncology, 2017, 12, S2020.	0.5	0
149	The Treatment of Malignant Pleural Mesothelioma: From the Current Standard to Novel Possible Therapeutic Strategies. , 2019, , 117-136.		0
150	Insert: An Overview on Current Clinical Trials. , 2019, , 143-145.		0
151	MST1R, a receptor tyrosine kinase expressed in malignant pleural mesothelioma.. Journal of Clinical Oncology, 2010, 28, 10583-10583.	0.8	0
152	Activation of the macrophage-stimulating protein (MSP)-RON axis in malignant pleural mesothelioma.. Journal of Clinical Oncology, 2011, 29, e17508-e17508.	0.8	0
153	The therapeutic potential of the novel ribonuclease ranpirnase (Onconase®) in the treatment of malignant mesothelioma. Oncology Reviews, 2011, 2, 61.	0.8	0
154	The therapeutic potential of the novel ribonuclease ranpirnase (Onconase®) in the treatment of malignant mesothelioma. Oncology Reviews, 0, , 61-65.	0.8	0